PASADENA, Calif. --(BUSINESS WIRE)--Sep. 2, 2026-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare
-- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- -- XmAb942 enrollment in XENITH-UC remains on track with primary endpoint of the 12-week
-- Agreement with Alexion resolves previously disclosed dispute regarding U.S. royalties -- -- Ex- U.S. royalties remain unchanged -- PASADENA, Calif. --(BUSINESS WIRE)--Jul. 29, 2026-- Xencor, Inc. (NASDAQ:XNCR) (“Xencor”), a clinical-stage biopharmaceutical company developing engineered
-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose -- -- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 -- PASADENA, Calif. --(BUSINESS WIRE)--Jul. 17, 2026-- Xencor, Inc.